NSE: GLENMARK · 7 October 2026
- Glenmark Pharmaceuticals shares declined 1.24% today, settling at ₹2,282.30 after touching an intraday high of ₹2,325.30 and a low of ₹2,274.40 from a previous close of ₹2,311.00.
- Glenmark Therapeutics Inc., USA announced the commercial launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product is comparable to the active ingredient of Differin Gel, 0.1%, a market that achieved annual sales of approximately $45.8 million according to Nielsen syndicated data for the 52-week period ending September 5, 2026. Management noted the new packaging enhances consumer convenience and strengthens its U.S. dermatology portfolio.
- Trading volume was 0.91 times the 20-day average daily volume.
Why is Glenmark Pharmaceuticals share price falling on 7 October 2026?
Glenmark Pharmaceuticals shares declined 1.24% today, settling at ₹2,282.30 after touching an intraday high of ₹2,325.30 and a low of ₹2,274.40 from a previous close of ₹2,311.00.
The broader market experienced downward pressure during the session, with the Nifty falling 0.76% and the Nifty Pharma sector benchmark retreating by 0.43%. Glenmark's decline of 1.24% slightly underperformed the broader healthcare sector and benchmark indices, extending a short-term pullback that includes a 2.24% loss over the past 5 trading days and a 6.27% drop across the past 20 trading days.
The price movement coincides with ongoing developments following the company's recent operational updates, including the October 06, 2026 launch of Adapalene Gel USP, 0.1% (OTC) in pump packs in the United States and the September 23, 2026 receipt of a U.S. FDA Establishment Inspection Report with VAI classification for its Goa facility. While these recent disclosures provide fundamental context regarding its product pipeline and regulatory progress, no single direct catalyst was announced today to explicitly drive the session's retracement.
4.98 lakh shares traded by 7 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 5.44 lakh shares (0.91 times). The five-day average daily volume was 6.44 lakh shares. Separately, the NSE report for 6 October 2026 showed 2.77 lakh shares delivered, representing 56.11% of that day’s traded volume. The same report recorded 40,035 trades.
The stock's 1.24% decline appears consistent with broader negative sentiment across headline indices and the pharma sector, combined with existing short-term retracement trends. No specific company-level event occurred today to prompt the move.
Latest Company Developments
Glenmark Therapeutics Inc., USA announced the commercial launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product is comparable to the active ingredient of Differin Gel, 0.1%, a market that achieved annual sales of approximately $45.8 million according to Nielsen syndicated data for the 52-week period ending September 5, 2026. Management noted the new packaging enhances consumer convenience and strengthens its U.S. dermatology portfolio.
Expands Glenmark's over-the-counter dermatology product offerings in the United States, targeting a well-established product category.
Glenmark Pharmaceuticals announced the receipt of the Establishment Inspection Report from the U.S. Food and Drug Administration for its formulations manufacturing facility in Goa, India. The inspection, conducted from June 22 to June 30, 2026, successfully closed with a Voluntary Action Indicated status. This classification indicates satisfactory resolution and compliance standards at the manufacturing site.
Clears regulatory scrutiny for a key manufacturing facility, supporting export visibility and compliance confidence for regulated markets.
Glenmark Specialty S.A. launched RYALTRIS Nasal Spray in Brazil for treating moderate to severe symptoms of allergic rhinitis in adults and adolescents aged 12 and older. The rollout follows regulatory approval from ANVISA and introduces the first olopatadine-containing intranasal combination therapy in Brazil. Allergic rhinitis affects an estimated 20-30% of the Brazilian population.
Broadens the global footprint of Glenmark's flagship innovative respiratory brand in Latin America's largest healthcare market.
a press release dated October 06, 2026, titled "Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)".
a press release dated October 06, 2026, titled "Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.76% on 30 June 2026. This compares with 16.80% on 31 March 2026, a change of -0.04 percentage points.
The filing reported 37 MF/UTI holders.
Research & Brokerage Views
Recommended as a stock pick by analyst Chandan Taparia, reflecting favorable technical positioning and growth outlook.
Maintained a hold rating with a price target of Rs 2100 based on valuation and near-term business trajectory.
What to Watch Next
- Sustained delivery percentage trends above 50% to gauge institutional and delivery-based accumulation
- Execution progress and revenue contribution from the recently launched Adapalene Gel pump packs in the U.S.
- Commercial ramp-up and market uptake of Ryaltris following its recent launch in Brazil
- Further updates regarding USFDA compliance status across other manufacturing facilities
Other Dated Coverage
- Why Glenmark Pharmaceuticals Shares Are Up 0.70% Today | 6 October 2026 — 6 October 2026
- Why Glenmark Shares Fell 1.54% Today: Sector Consolidation | 5 October 2026 — 5 October 2026
- Why Glenmark Shares Fell 4.37% Today: Sector Headwinds & Volume Analysis | 30 September 2026 — 30 September 2026
More Glenmark Pharmaceuticals news and dated analysis →
Frequently Asked Questions
What is the latest Glenmark Pharmaceuticals company news?
Glenmark Therapeutics Inc., USA announced the commercial launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product is comparable to the active ingredient of Differin Gel, 0.1%, a market that achieved annual sales of approximately $45.8 million according to Nielsen syndicated data for the 52-week period ending September 5, 2026. Management noted the new packaging enhances consumer convenience and strengthens its U.S. dermatology portfolio.
How strong was Glenmark Pharmaceuticals’s trading volume?
4.98 lakh shares traded, 0.91 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.